Topical pain relief:
Indications for: ZINGO
To provide local analgesia prior to venipuncture in adults and children or peripheral IV cannulation in children.
Adults and Children:
<3yrs: not established. ≥3yrs: Use only on intact skin. Apply one 0.5mg dose to the planned procedure site 1–3 mins before needle insertion; may repeat once at new site after initial attempt failed. Multiple administrations to same site: not recommended.
ZINGO Warnings/Precautions:
Avoid eyes, body orifices, mucous membranes or areas with a compromised skin barrier. Severe hepatic disease or pseudocholinesterase deficiency. Bleeding tendencies or platelet disorders: higher risk of superficial dermal bleeding. Risk of methemoglobinemia (esp. in G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants <6 months of age, concurrent exposure to oxidizing agents or metabolites); monitor. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
ZINGO Classification:
Local anesthetic (amide-type).
ZINGO Interactions:
Increased risk of methemoglobinemia when concurrently exposed to nitrates/nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, others.
Adverse Reactions:
Application-site reactions (eg, erythema, petechiae, edema, pruritus), systemic reactions (eg, nausea, vomiting), dizziness.
Generic Drug Availability:
NO
How Supplied:
Single-use device (disposable, needle-free)—12
